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To identify favored choice of transplantation in patients with acute promyelocytic leukemia (APL) in second
complete remission, we studied 294 patients with APL in second complete remission (CR2) receiving allo-
geneic (n ¼ 232) or autologous (n ¼ 62) hematopoietic cell transplantation (HCT) reported to the Center for
International Blood and Marrow Transplantation Research (CIBMTR) from 1995 to 2006, including 155 with
pre-HCT PML/RARf status (49% of allogeneic and 66% of autologous). Patient characteristics and trans-
plantation characteristics, including treatment-related mortality, overall survival (OS), and disease-free sur-
vival, were collected and analyzed for both univariate and multivariate outcomes. With median follow-up of
115 (allogeneic) and 72 months (autologous), 5-year disease-free survival (DFS) favored autologous with 63%
(49% to 75%), compared with allogeneic at 50% (44% to 57%) (P ¼ .10). OS was 75% (63% to 85%) versus 54%
(48% to 61%) (P ¼ .002), for autologous and allogeneic transplantation, respectively. Multivariate analysis
showed signiﬁcantly worse DFS after allogeneic HCT (hazard ratio [HR], 1.88; 95% conﬁdence interval [CI], 1.16
to 3.06; P ¼ .011) and age > 40 years (HR, 2.30; 95% CI, 1.44 to 3.67; P ¼ .0005). OS was signiﬁcantly worse
after allogeneic HCT (HR, 2.66; 95% CI, 1.52 to 4.65; P ¼ .0006); age > 40 (HR, 3.29; 95% CI, 1.95 to 5.54;
P < .001), and ﬁrst complete remission < 12 months (HR, 1.56; 95% CI, 1.07 to 2.26; P ¼ .021). Positive pre-HCT
PML-RARf status in 17 of 114 allogeneic and 6 of 41 receiving autologous transplantation did not inﬂuence
relapse, treatment failure, or survival in either group. The survival advantage for autografting was attributable
to increased treatment-related mortality (TRM) in the allogeneic group of 30% compared to 2% in the
autologous group, in addition to the added mortality associated with GVHD. We conclude that autologous
HCT yields superior OS for APL in CR2. Long-term DFS in autologous recipients, even with minimal residual
diseaseepositive grafts, remains an important subject for further study.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute promyelocytic leukemia (APL) accounts for 10% to
15% of de novo acute myeloid leukemia in younger adults [1].
Therapeutic strategies of all-trans retinoic acid, anthracycline-
based induction, and recently, arsenic trioxide (ATO) yield
remission rates of approximately 90%, most of which are du-
rablewith 2-year disease-free survival (DFS) of 79% and overall
survival (OS) of 92% [2,3]. For the 10% to 20% of patients who
relapse, recent evidence suggests that ATO reinduction candgments on page 1024.
equests: Jennifer L. Holter Chakrabarty,
3, Oklahoma City, OK 73104.
.edu (J.L. Holter Chakrabarty).
2014 American Society for Blood and Marrow
14.03.025lead to second complete remission (CR2) in up to 85% of
relapsed, previously arsenic-naïve patients [4,5]. Although
hematopoietic cell transplantation (HCT) is the generally
accepted therapy for APL in CR2, the choice of allogeneic
versus autologous HCT remains controversial. It is uncer-
tain whether the increased treatment-related mortality
(TRM) generally associated with allografts is compensated
for by a lower relapse rate due to a graft-versus-APL effect.
It has also been suggested that the outcome for autologous
HCT is best if molecularly negative cells are collected [6,7],
but the relative impact of persistent PML-RARf transcripts
before allograft or autologous HCT on outcome is uncer-
tain. In this retrospective study, we analyzed allogeneicTransplantation.
Table 1
Patient and Transplantation Characteristics
Patient Characteristics Allogeneic Autologous P
Value
Patients, n 232 62
Age at transplantation, n (%) < .001
<20 years 70 (30) 9 (15)
20-40 years 93 (40) 19 (31)
>40 years 69 (30) 34 (55)
Year of HCT < .001
1995-2000 145 (63) 25 (40)
2001-2006 87 (38) 37 (60)
Sex .18
Male 116 (50) 37 (60)
Female 116 (50) 25 (40)
KPS .91
> 90% 178 (77) 46 (74)
< 90% 48 (21) 14 (23)
Data missing 6 (3) 2 (3)
Time from CR1 to relapse,
median, (range), mo
14 (< 1-87) 17 (< 1-85) .08
<12 months 83 (36) 18 (29)
>12 Months 130 (56) 33 (53)
Data missing 19 (8) 11 (18)
Time from CR2 to HCT,
median (range), mo
2 (< 1-45) 2 (< 1-10) .19
<6 months 202 (87) 59 (95)
>6 months 28 (12) 3 (5)
Data missing 2 (< 1) –
Conditioning regimen
Myeloablative 213 (92) 55 (89)
RIC 15 (7) 5 (8)
Data missing 4 (2) 2 (4)
TBI containing 116 (50) 47 (76) .001
Non-TBI 114 (49) 15 (24)
Donor type N/A
HLA-identical Sibling 124 (53)
URD well/partially matched 63 (27)
Other related 45 (19)
Stem cell source < .001
Marrow 154 (66) 8 (12)
Peripheral blood 78 (34) 54 (88)
GVHD prophylaxis N/A
CSA/Tac  MMF 203 (88)
T cell depletion þ post-HCT
immunosuppression
24 (10)
Other 5 (2)
KPS indicates Karnofsky performance score (before conditioning); RIC,
reduced-intensity conditioning; TBI, total body irradiation; URD, unrelated
donor; GVHD, graft-versus-host disease; CSA, cyclosporine; Tac, tacrolimus;
MMF, mycophenolate mofetil; CR1, ﬁrst complete remission; CR2, second
complete remission; HCT, hematopoietic cell transplantation.
Data presented are n (%) unless otherwise indicated.
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survival outcomes and to evaluate the impact of residual
molecularly detectable pretransplantation marrow disease
on outcome.
METHODS
This multi-institutional, international, retrospective study used data on
autologous and allogeneic HCT for APL in CR2 reported to the Center for
International Blood and Marrow Transplant Research (CIBMTR) from 79
centers in 18 countries during the years 1995 to 2006. Variables analyzed for
their inﬂuence on outcome included age, time from ﬁrst complete remission
(CR1) to relapse (< or >12 months), and, for allografts, type of donor. In
addition to the information available from standard CIBMTR report forms,
supplemental data were retrieved from the HCT centers to determine mo-
lecular and cytogenetic results before HCT, time from second complete
remission (CR2) to transplantation, and therapy used to attain CR2. Evidence
of positivity of disease status just before transplantation deﬁned minimal
residual disease (MRD). Supplemental forms collected both quantitative and
qualitative molecular and cytogenetic data for establishment of MRD. Sup-
plemental data were retrieved in 114 of 232 (49%) of allogeneic and 41 of 62
(66%) of autologous cases.
Clinical and demographic characteristics of the 2 groups were examined
using chi-square statistics. Additional analyses compared the characteristics
of patients with or without the requested supplemental data to insure
generalizability of data from the smaller cohort with this added detail
available. Deﬁned endpoints included DFS as the time from HCT to death or
relapse. Relapse was deﬁned as time to hematologic recurrence and TRM
was deﬁned as death within the ﬁrst 21 days or death before relapse. Overall
survival (OS) was calculated as the time from HCT to death or last contact
alive. Statistical analysis was performed using proportional hazards
regression models. The proportional hazards assumptions for all variables
were examined and all variables met the assumptions. A stepwise selection
procedure was used to select variables signiﬁcantly associated with the
outcomes. Because the type of transplantation was the main effect of in-
terest, it was included in all steps of the model building process. Risk factors
with a signiﬁcance level of .05 were included in the ﬁnal models. The
interaction between the main effect of transplantation type and all signiﬁ-
cant covariates was examined and no interaction was found to be statisti-
cally signiﬁcant. All analyses were conducted using SAS V9.3 (SAS Institute,
Cary, NC).
RESULTS
Patient characteristics and transplantation-related factors
are shown in Table 1. The numbers of allogeneic HCT
decreased over time, whereas the relative number of autol-
ogous HCT increased in more recent years.
Patient demographics, including Karnofsky performance
status and sex, were not statistically different between
allogeneic and autologous recipients. However, allogeneic
recipients were signiﬁcantly younger. Disease-related factors
including histologic subtype, white blood cell (WBC) count at
diagnosis, cytogenetic and/or molecular positivity at diag-
nosis, time from CR1 to relapse, and time from CR2 to
transplantation were not signiﬁcantly different. The use of
ATO occurred during the period of study, representing a
major change in the treatment of APL. For this reason, we
evaluated the impact of ATO therapy before transplantation.
In univariate and multivariate analysis, we observed no
impact of ATO-containing versus non-ATO pre-HCT therapy
on the risk of relapse after HCT (hazard ratio [HR], .598; 95%
conﬁdence interval [CI], .230 to 1.456; P ¼ .25).
The vast majority of autologous transplantations were
myeloablative, using standard regimens, most often total
body irradiation (TBI) (Table 1). Univariate outcomes are
shown in Table 2, with favorable OS, DFS, and TRM observed
in autologous HCT. Only a modest and not signiﬁcant
reduction in relapse followed allogeneic HCT. Five-year OS
for the autologous cohort was 75% (95% CI, 63% to 85%) and
for the allogeneic cohort, 54% (95% CI, 48% to 61%) (Figure 1).
The risk of overall mortality (inverse of OS) was higher after
allogeneic transplantation compared with autologous (HR,2.66; 95% CI, 1.52 to 4.65; P ¼ .0006). DFS at 5 years also
favored autologous HCT: 63% (49% to 75%) compared with
50% (44% to 57%) in allogeneic cohort (Figure 2). Equivalently,
the risk of treatment failure (inverse of DFS) was higher after
allogeneic transplantation (HR, 1.88; 95% CI, 1.16 to 3.06;
P ¼ .011). Multivariate analysis showed that age > 40 years
also adversely inﬂuenced overall mortality (HR, 3.29; 95% CI,
1.95 to 5.54; P< .001) and treatment failure, with a HR of 2.30
(95% CI, 1.44 to 3.67); P ¼ .0005. A shorter duration of CR1
(< 12 months) was associated with signiﬁcantly higher
mortality (HR, 1.56; 95% CI, 1.07 to 2.26; P ¼ .02).
The molecular status of PML-RARf transcripts or cy-
togenetic translocations detectable in the pre-HCT bone
marrow were studied for their inﬂuence on relapse and
other HCT outcomes. The demographics of the cohorts
with these additional data are shown in supplemental
Table S1. Surprisingly, in both autologous (n ¼ 6 of 41)
and allogeneic HCT (n ¼ 17 of 114), molecular or cytoge-
netically positive grafts were not associated with increased
Figure 2. Disease-free survival in patients undergoing allogeneic and autolo-
gous transplantation for APL in CR2.
Table 2
Univariate Probability of Outcome
Outcomes Allogeneic
(n ¼ 232)
Autologous
(n ¼ 62)
P Value
n Prob
(95% CI), %
n Prob
(95% CI), %
Relapse 230 61
1 year 10 (6-14) 21 (11-32) .14
3 year 16 (12-22) 28 (17-40) .34
5 year 18 (14-24) 30 (19-42) .40
Treatment-related mortality 230 61
1 year 28 (22-34) 2 (0-8) < .001
3 year 30 (24-36) 5 (1-14) < .001
5 year 31 (25-37) 7 (2-17) < .001
Disease-free survival 230 61
1 year 62 (56-68) 78 (66-87) .02
3 year 54 (47-60) 67 (54-78) .07
5 year 50 (44-57) 63 (49-75) .10
Overall survival 232 62
1 year 66 (60-72) 93 (85-98) < .001
3 year 58 (52-65) 79 (67-88) .002
5 year 54 (48-61) 75 (63-85) .002
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pre-HCT was 17% (95% CI, 0 to 55%) versus negative grafts,
24% (95% CI, 10% to 41%); P ¼ .69; for allogeneic positive,
27% (95% CI, 8% to 51%) versus negative, 16% (95% CI, 9% to
25%); P ¼ .38. DFS with autologous positive pre-HCT was
83% (95% CI, 46% to 100%) versus negative grafts, 69% (95% CI,
51% to 84%); P ¼ .41; allogeneic positive pre-HCT, 60% (95% CI,
35% to 82%) versus negative, 62% (95% CI, 51% to 73%); P ¼ .87.
Overall survival with autologous positive pre-HCT was 83%
(95% CI, 46% to 100%) versus negative grafts, 77% (95% CI, 60%
to 90%); P ¼ .70; allogeneic positive, 65% (95% CI, 41% to 85%)
versus negative, 66% (95% CI, 55% to 76%); P ¼ .90.
Multivariate analysis conﬁrmed that positive molecular
or cytogenetic status was not signiﬁcantly associated with
overall mortality (positive, HR, .73; 95% CI, .318 to 1.651;
P ¼ .44). In the allogeneic group with positive molecular or
cytogenetically detectable disease before HCT, the relapse
rate at 5 years was 27% (95% CI, 8% to 51%), DFS was 60% (95%
CI, 35% to 82%), and OS was 65% (95% CI, 41% to 85%). All were
similar to these corresponding outcomes in those who had
negative pre-HCT ﬁndings. Notably, in the autologous group,Figure 1. Overall survival in patients undergoing allogeneic and autologous
transplantation with APL in CR2.only 6 patients had positive cytogenetic or molecular testing
before HCT, yet of these 6, 1 relapsed at 6 months and died
11 months after HCT. Five remain alive and disease free at 47,
60, 61, 72, and 129 months after HCT. We acknowledge the
small numbers of patients with positive grafts makes any
ﬁrm conclusions difﬁcult.
In the allogeneic group, the cumulative incidence of acute
GVHD grade II to IV at 100 days was 33% (95% CI, 27% to 40%),
whereas chronic GVHD at 5 years was 45% (95% CI, 38% to
52%), consistent with established rates in allogeneic HCT.
Figure 3 shows the cumulative incidence of TRM in the 2
cohorts. Causes of death for all patients (123 of 294) were
primarily leukemia recurrence (n ¼ 33), new malignancy
(n ¼ 4), idiopathic pneumonia syndrome (n ¼ 17), infection
(n¼ 17), and organ failure (n ¼ 21). The causes of death in
allogeneic transplantation group (n ¼ 107 of 232) were less
often APL recurrence (n ¼ 27), but more often due to toxic-
ities, including organ toxicity/failure (n¼ 18), GVHD (n¼ 16),
infection (n ¼ 15), idiopathic pneumonia syndrome (n ¼ 15),
and others (2 graft failure, 2 hemorrhage, 1 thromboembolic,
and 6 other not speciﬁed).Figure 3. Treatment-related mortality in patients undergoing allogeneic and
autologous transplantation for APL in CR2.
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This large, multinational series demonstrated that the
preferred therapy for APL in CR2 is autologous over alloge-
neic HCT. The signiﬁcantly greater TRM of the allogeneic HCT
is not overcome by the modest but not signiﬁcantly better
protection against relapse accompanying the allogeneic
graft process, even when adjusted for the molecular or
cytogenetic status of the patient before HCT in CR2 [7]. An
earlier analysis by the European Cooperative Group for
Blood and Marrow Transplantation reviewed 625 patients
with APL who underwent transplantation by either
autologous or allogeneic HSCT in either CR1 or CR2 from
1993 to 2003 [8]. Patients in CR2 (n ¼ 195) had lower
relapse rates after allogeneic HCT (37%  4% autologous
versus 17%  3%) and 5-year leukemia-free survival of 51%
 4% autologous versus 59%  4% after allografts. Autolo-
gous transplantations for APL in this study had a higher
TRM of 16%  3%. The higher than expected TRM in the
autologous arm led to a small difference of TRM between
allogeneic transplants (24%  4%). Allogeneic HCT was
recommended in CR2 when a sibling donor was available
[8].
Few data on molecular-positive patients who underwent
transplantation during CR2 are available. Meloni et al.
analyzed 15 patients with relapsed APL undergoing autolo-
gous HCT, and PCR-negative pre-HCTmarrow led to 45% (6 of
15) of patients remaining in remission [9]. However, 7 of 7
patients with PCR-positive marrow relapsed within 9
months of autologous HCT. They recommended allogeneic
HCT if the pre-HCT marrow was cytogenetically or molecu-
larly positive. Sanz et al. described a single patient in CR2
with molecular positivity on preconditioning marrow who
received an autologous HCT and survived leukemia free 22
months after HCT [10].
After ﬁrst relapse, several highly effective strategies for
APL include ATO for reinduction and transplantation dur-
ing CR2 [11]. Our data highlight that, despite continued
improvements in supportive care and improvements in
management of GVHD, the substantial excess of TRM limits
survival for allogeneic HCT patients with APL in CR2.
Somewhat surprisingly, pretransplantation molecular and
cytogenetic positivity identifying detectable residual dis-
ease at HCT had no signiﬁcant inﬂuence on treatment
failure. In contrast to the ﬁndings of Meloni et al., and in an
admittedly small cohort, residual detectable disease rarely
led to failure in the autologous group with 5 of 6 patients
remaining disease free. This observation suggests that
effective eradication of residual disease in vivo, preferen-
tial mobilization into the autograft of short-term repopu-
lating cells, but too few leukemia stem cells to induce
relapse [12], a modest purging effect of cryopreser-
vation on unstable leukemic clones or other mechanisms
may be protective and offers opportunities for further
investigation.
The remarkable success obtained with the newest
strategy, all-trans retinoic acid plus ATO for initial therapy,
will likely lead to less relapse and decrease in the need for
any kind of transplantation [13]. However, these data
further clarify that APL exhibits unique characteristics,
making it amenable to autologous HCT, compared with
other types of leukemia, where allogeneic HCT may be
preferred. These data provide evidence that autologous
HCT for APL is the superior treatment strategy, leading to
long-term remission and survival for a large proportion of
patients in CR2.ACKNOWLEDGMENTS
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